{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:47:10Z","timestamp":1787510830869,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jhepr.2024.101070","type":"journal-article","created":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T17:50:28Z","timestamp":1711302628000},"page":"101070","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2582-7798","authenticated-orcid":false,"given":"Selma","family":"El Messaoudi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7336-7730","authenticated-orcid":false,"given":"S\u00e9gol\u00e8ne","family":"Brichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2736-6769","authenticated-orcid":false,"given":"Claire","family":"Fougerou-Leurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2664-9417","authenticated-orcid":false,"given":"Emmanuel","family":"Gordien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athena\u00efs","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Kortebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garance","family":"Lagadic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslava","family":"Subic-Levrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3538-6498","authenticated-orcid":false,"given":"Sophie","family":"Metivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Minello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Ratziu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Mathurin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0676-7539","authenticated-orcid":false,"given":"Laurent","family":"Alric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatoumata","family":"Coulibaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0745-7559","authenticated-orcid":false,"given":"Jean-Michel","family":"Pawlotsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2245-0083","authenticated-orcid":false,"given":"Fabien","family":"Zoulim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"de L\u00e9dinghen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie","family":"Guedj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2024.101070_bib1","year":"2021","journal-title":"viral Hepat Sex Transm infections"},{"key":"10.1016\/j.jhepr.2024.101070_bib2","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/hep.29323","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"66","author":"Lok","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2024.101070_bib3","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0168-8278(03)00331-3","article-title":"Delta hepatitis: an update","volume":"39","author":"Farci","year":"2003","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2024.101070_bib4","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.3390\/v14081749","article-title":"A\u00a0review of HDV infection","volume":"14","author":"Caviglia","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.jhepr.2024.101070_bib5","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S1590-8658(10)60688-3","article-title":"Hepatitis delta virus infection: open issues","volume":"43","author":"Niro","year":"2011","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhepr.2024.101070_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhepr.2024.101070_bib7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2024.101070_bib8","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhepr.2024.101070_bib9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/apt.12788","article-title":"Long-term therapy of chronic delta hepatitis with peginterferon alfa","volume":"40","author":"Heller","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.jhepr.2024.101070_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/liv.15410","article-title":"Interferon-based treatment of chronic hepatitis D","volume":"43","author":"Sandmann","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2024.101070_bib11","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3851\/IMP2728","article-title":"Treatment of chronic hepatitis D patients with pegylated interferon: a real-world experience","volume":"19","author":"Abbas","year":"2014","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhepr.2024.101070_bib12","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhepr.2024.101070_bib13","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1136\/gutjnl-2020-323888","article-title":"Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease","volume":"70","author":"Urban","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2024.101070_bib14","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/apt.16945","article-title":"Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a \u201creal world\u201d study","volume":"56","author":"Jachs","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.jhepr.2024.101070_bib15","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.jhep.2016.02.016","article-title":"New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus","volume":"64","author":"Durantel","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2024.101070_bib16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa2213429","article-title":"A\u00a0phase 3, randomized trial of bulevirtide in chronic hepatitis D","volume":"389","author":"Wedemeyer","year":"2023","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhepr.2024.101070_bib17","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.3390\/cells11223531","article-title":"Treatment of chronic hepatitis D with bulevirtide\u2014a fight against two foes\u2014an update","volume":"11","author":"Ferenci","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jhepr.2024.101070_bib18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/DDDT.S379964","article-title":"Bulevirtide in the treatment of hepatitis delta: drug discovery, clinical development and place in therapy","volume":"17","author":"Soriano","year":"2023","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jhepr.2024.101070_bib19","unstructured":"Asselah T, Lampertico P, Wedemeyer H et\u00a0al. Efficacy and safety of bulevirtide in combination with pegylated interferon alfa-2a in patients with chronic hepatitis delta: primary endpoint results from a phase 2b open-label, randomized, multicenter study MYR204. https:\/\/www.natap.org\/2023\/AASLD\/AASLD_60.htm Accessed December 1,\u00a02023."},{"key":"10.1016\/j.jhepr.2024.101070_bib20","doi-asserted-by":"crossref","unstructured":"Wedemeyer H, Bogomolov P, Blank A et\u00a0al. Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of MyrcludexB in combination with Tenofovirin patients with HBV\/HDV coinfection. https:\/\/www.natap.org\/2018\/EASL\/EASL_88.htm Accessed August 1,\u00a02023.","DOI":"10.1016\/S0168-8278(18)30224-1"},{"key":"10.1016\/j.jhepr.2024.101070_bib21","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","article-title":"Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib\/IIa study","volume":"65","author":"Bogomolov","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.jhepr.2024.101070_bib22","first-page":"26","article-title":"Bulevirtide-based treatment strategies for chronic hepatitis delta: a review","volume":"30","author":"Degasperi","year":"2023","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhepr.2024.101070_bib23","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/clpt.2010.35","article-title":"A\u00a0comprehensive hepatitis C viral kinetic model explaining cure","volume":"87","author":"Snoeck","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2024.101070_bib24","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/sim.4191","article-title":"Design evaluation and optimization for models of hepatitis C viral dynamics","volume":"30","author":"Guedj","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.jhepr.2024.101070_bib25","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/psp4.28","article-title":"HCV Kinetic models and their implications in drug development","volume":"4","author":"Nguyen","year":"2015","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.jhepr.2024.101070_bib26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/imr.12686","article-title":"Modeling the dynamics of hepatitis B infection, immunity, and drug therapy","volume":"285","author":"Ciupe","year":"2018","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jhepr.2024.101070_bib27","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/cpt.2798","article-title":"A\u00a0semi-mechanistic model to characterize the long-term dynamics of hepatitis B virus markers during treatment with lamivudine and pegylated interferon","volume":"113","author":"El Messaoudi","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2024.101070_bib28","first-page":"3323","article-title":"A\u00a0mathematical model for early HBV and -HDV kinetics during anti-HDV treatment","volume":"9","author":"Zakh","year":"2021","journal-title":"Mathematics (Basel)"},{"key":"10.1016\/j.jhepr.2024.101070_bib29","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/jvh.13425","article-title":"What drives the dynamics of HBV RNA during treatment?","volume":"28","author":"Gon\u00e7alves","year":"2021","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhepr.2024.101070_bib30","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1086\/656528","article-title":"Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections","volume":"202","author":"Ribeiro","year":"2010","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhepr.2024.101070_bib31","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/hep.22874","article-title":"Hepatitis B virus clearance rate estimates","volume":"49","author":"Dahari","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2024.101070_bib32","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41598-020-80594-6","article-title":"Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection","volume":"11","author":"Kadelka","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2024.101070_bib33","article-title":"Modelling HDV kinetics under entry-inhibitor Bulevirtide suggests the existence of two HDV-infected cell populations","volume":"6","author":"Shekhtman","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2024.101070_bib34","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrgastro.2015.97","article-title":"Modelling hepatitis C therapy \u2013 predicting effects of treatment","volume":"12","author":"Perelson","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2024.101070_bib35","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.antiviral.2017.06.019","article-title":"Modeling HCV cure after an ultra-short duration of therapy with direct acting agents","volume":"144","author":"Goyal","year":"2017","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhepr.2024.101070_bib36","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nature03153","article-title":"Modelling how ribavirin improves interferon response rates in hepatitis C virus infection","volume":"432","author":"Dixit","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2024.101070_bib37","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1053\/jhep.2003.50344","article-title":"Dynamics of alanine aminotransferase during hepatitis C virus treatment","volume":"38","author":"Ribeiro","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2024.101070_bib38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41577-021-00549-4","article-title":"Immunobiology and pathogenesis of hepatitis B virus infection","volume":"22","author":"Iannacone","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhepr.2024.101070_bib39","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in\u00a0vivo and the antiviral efficacy of interferon-\u03b1 therapy","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jhepr.2024.101070_bib40","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1002\/hep.27357","article-title":"Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling","volume":"60","author":"Guedj","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2024.101070_bib41","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/hep.24788","article-title":"Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128)","volume":"55","author":"Guedj","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2024.101070_bib42","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.3748\/wjg.v18.i40.5793","article-title":"Treatment of chronic hepatitis delta virus with peg-interferon and factors that predict sustained viral response","volume":"18","author":"Samiullah","year":"2012","journal-title":"World J Gastroenterol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555924000715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555924000715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T07:54:10Z","timestamp":1728374050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555924000715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2589555924000715"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2024.101070","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2024.101070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101070"}}